Media Coverage_Press Release_InxMed-Leading Innovations Targeting Tumor Defense

17

2022-03

2022-03-17

BioWorld：Inxmed raises $50M to develop cancer therapy in the US, China

Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.

20

2019-06

2019-06-20

Dialogue | interview with Dr. Wang Zaiqi, chairman of the Organizing Committee of the 5th dia China Pharmaceutical R & D Innovation Conference in 2009

In June 2019, New England magazine published the major research achievement of Tu youyou's team - "artemisinin resistance" treatment response plan. This is an important achievement of China in the field of global drug R & D. Benchmarking international, China's R & D of innovative drugs has attracted worldwide attention.

29

2019-07

2019-07-29

Freehand character Wang Zaiqi: research and development of individualized therapeutic drugs with global influence

Dr. Wang Zaiqi will attend the global clinical research and development failure and success case analysis, the 96th activity of the same freehand brushwork forum for the third time, and make a special report - "the experience of using anti-PD-1 combined chemotherapy drugs in gastric cancer chemotherapy - excellent early trial data and disappointing phase 3 results. What have we learned?"

BioWorld：Inxmed raises $50M to develop cancer therapy in the US, China

Dialogue | interview with Dr. Wang Zaiqi, chairman of the Organizing Committee of the 5th dia China Pharmaceutical R & D Innovation Conference in 2009

Freehand character Wang Zaiqi: research and development of individualized therapeutic drugs with global influence

QUICK LINKS

CONTACT US

MESSAGE